ELUT vs. PLX, ATHA, CGTX, CVM, GRTS, TIL, DTIL, TSBX, ALVR, and PASG
Should you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), Cognition Therapeutics (CGTX), CEL-SCI (CVM), Gritstone bio (GRTS), Instil Bio (TIL), Precision BioSciences (DTIL), Turnstone Biologics (TSBX), AlloVir (ALVR), and Passage Bio (PASG). These companies are all part of the "biological products, except diagnostic" industry.
Elutia (NASDAQ:ELUT) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
74.0% of Elutia shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 40.8% of Elutia shares are owned by insiders. Comparatively, 5.0% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Protalix BioTherapeutics has higher revenue and earnings than Elutia. Elutia is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Protalix BioTherapeutics had 1 more articles in the media than Elutia. MarketBeat recorded 4 mentions for Protalix BioTherapeutics and 3 mentions for Elutia. Protalix BioTherapeutics' average media sentiment score of 0.14 beat Elutia's score of -0.33 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.
Elutia and Protalix BioTherapeutics both received 5 outperform votes by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 62.50% of users gave Protalix BioTherapeutics an outperform vote.
Elutia has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.
Elutia presently has a consensus target price of $5.00, suggesting a potential upside of 51.06%. Protalix BioTherapeutics has a consensus target price of $10.00, suggesting a potential upside of 777.19%. Given Protalix BioTherapeutics' higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Elutia.
Protalix BioTherapeutics has a net margin of 11.48% compared to Elutia's net margin of -164.45%. Protalix BioTherapeutics' return on equity of 19.48% beat Elutia's return on equity.
Summary
Protalix BioTherapeutics beats Elutia on 11 of the 16 factors compared between the two stocks.
Get Elutia News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
